# A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

> **NCT02613208** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 111 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02613208
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-09
- **Primary completion:** 2018-12-03
- **Final completion:** 2018-12-03
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613208, "A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02613208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*